Stephen H Monroe

US Patent:

20030133991, Jul 17, 2003

Filed:

Nov 27, 2002

Appl. No.:

10/305713

Inventors:

Stephen Monroe - Memphis TN, US
Hans Hoekstra - Memphis TN, US

Assignee:

Greystone Medical Group, Inc. - Memphis TN

International Classification:

A61K033/32
A61K033/00
A61K031/19

US Classification:

424/642000, 424/722000, 514/574000

Abstract:

A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.

US Patent:

20040023937, Feb 5, 2004

Filed:

May 22, 2003

Appl. No.:

10/443476

Inventors:

Stephen Monroe - Memphis TN, US

Assignee:

Greystone Medical Group, Inc. - Memphis TN

International Classification:

A61K035/78
A61K031/573

US Classification:

514/179000, 424/779000

Abstract:

Composition for halting the metastasis of cancer cells comprising rubidum ursolate. The rubidium ursolate is formed from a mixture of rubidium and ursolic acid obtained from the bark of the Virburnum plant.

US Patent:

20040105897, Jun 3, 2004

Filed:

Aug 21, 2003

Appl. No.:

10/645410

Inventors:

Stephen Monroe - Memphis TN, US
Hans Hoekstra - Amsterdan, NL

Assignee:

Greystone Medical Group, Inc. - Memphis TN

International Classification:

A61K033/32
A61K033/00

US Classification:

424/641000, 424/722000

Abstract:

A synthesized composition containing one or more of zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when administered to a patient in need thereof, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method is disclosed.

US Patent:

20040170703, Sep 2, 2004

Filed:

Dec 23, 2003

Appl. No.:

10/744699

Inventors:

Hans Hoekstra - Amsterdam, NL
Stephen Monroe - Memphis TN, US
A. J. J. Van Den Berg - Utrecht, NL

Assignee:

Greystone Medical Group, Inc. - Memphis TN

International Classification:

A61K033/32
A61K033/06
A61K033/00

US Classification:

424/642000, 424/682000, 424/722000

Abstract:

Reactive oxygen species associated with a wound are modulated through treatment of the wound with a solution of metal ions selected from the group consisting of potassium ions, zinc ions, calcium ions and rubidium ions, at a pH of between about 5 and about 7. Preferably, citric acid is employed to adjust the pH of the solution. Application of the extract to a wound exhibiting superoxide anions has been found to be effective in the treatment of these wounds through the reduction of the level of superoxide anions. Moreover, treatment of partial thickness excision wounds as well as contact burn wounds with the present composition has been found to improve epithelialization of these wounds. In addition to the antioxidant activity of the present invention, treatment of the wound employing the present composition produces inhibitory effects on ROS production by human PMNs and on human complement activation, and therefore, is further beneficial in chronic wound management.

US Patent:

20050014838, Jan 20, 2005

Filed:

Jun 29, 2004

Appl. No.:

10/879380

Inventors:

Stephen Monroe - Memphis TN, US
Robert Moore - Nesbitt MS, US

International Classification:

A61K031/557

US Classification:

514573000, 514613000

Abstract:

A method for treating vascular degeneration and stimulating glucose uptake in diabetics including the administration to a patient of a combination of a dilator of striated muscle microvasculature and chemical entity that stimulates the uptake of glucose in striated muscle in a pharmaceutically acceptable carrier.

US Patent:

20050175715, Aug 11, 2005

Filed:

Aug 25, 2004

Appl. No.:

10/925733

Inventors:

Stephen Monroe - Memphis TN, US
Robert Moore - Nesbitt MS, US

International Classification:

A61K031/505
A61K031/44
A01N033/12
A61K031/14

US Classification:

424722000, 514269000, 514352000, 514456000, 514642000

Abstract:

A mechanism is disclosed wherein depolarization of the cells associated with disease states, wherein matrix metalloproteinases are implicated as a contributor to the pathology of the disease state, and the subsequent regulation of certain proteins beneficially aids control of the matrix metalloproteinases. This initiating trigger can ultimately result in the down-regulation or up-regulation of matrix metalloproteinases. An example is given wherein matrix metalloproteinase 2 (MMP 2) is down-regulated.

US Patent:

20060029682, Feb 9, 2006

Filed:

Mar 15, 2005

Appl. No.:

11/081119

Inventors:

Stephen Monroe - Memphis TN, US
Matthias Hoekstra - Amsterdam, NL

International Classification:

A61K 33/32
A61K 33/00

US Classification:

424642000, 424722000

Abstract:

A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.

US Patent:

20070009611, Jan 11, 2007

Filed:

Sep 20, 2006

Appl. No.:

11/523869

Inventors:

Stephen Monroe - Memphis TN, US
Matthias Hoekstra - Amsterdam, NL

International Classification:

A61K 33/32
A61K 33/00
A61K 31/19

US Classification:

424641000, 424722000, 514574000

Abstract:

A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates-the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.